Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

Table 2 PDX models of triple-negative breast cancers

PDX	Patient source^a	Patient treatment^b	HER2 status^c	ER status	PR status	EGFR H-score^d	BCL-2 H-score^e	BCL-X_L H-score
HCI-001	PT	+ Prior T×	–	–	–	188	10	100
HCI-002	PT	− Prior T×	–	–	–	121	230	90
HCI-004	PT	− Prior T×	–	–	–	76	10	220
HCI-010	PE	+ Prior T×	–	–	–	228	10	10
HCI-015	MT	+ Prior T×	–	–	–	193	20	60
HCI-016	PT	− Prior T×	–	–	–	90	280	90
HCI-019	PT	− Prior T×	–	–	–	208	40	155

^aPT primary breast tumor, PE pleural effusion, MT metastatic breast tumor
^bT×, treatment as previously described [16] and unpublished data kindly provided by A.W.
^cHER2, ER, and PR as previously described [16] and unpublished data kindly provided by A.W.
^dH-score represents the average of 4–6 tumors per PDX
^eH-score represents one tumor surveyed per PDX kindly provided by A.W.

ISSN: 1465-542X